BioTheranostics Raises $32M in Private Equity Financing; Will Spin Off From BioMérieux | GenomeWeb

NEW YORK (GenomeWeb) – BioTheranostics announced today that it has raised $32 million in a private equity financing round, and will be spun off from parent company BioMérieux as a result.

The financing round was led by MVM Life Science Partners, with participation from Canepa Advanced Healthcare Fund and HealthQuest Capital. BioMérieux will remain a minority shareholder in the newly independent company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.